BBZA.XETRA BB Biotech AG

Healthcare Biotechnology XETRA Stock Exchange
55.40 EUR
Close of Nov 6, 2026
41.09 60.80
Market cap
EUR 3.06B
P/E
-
P/B
0.93x
ROE
25.2%
Dividend yield
5.65%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BBZA.XETRA undervalued?

Graham number

The Graham number of BB Biotech AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BB Biotech AG fundamental analysis

No fundamental analysis for BB Biotech AG yet.

BB Biotech AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BB Biotech AG

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

Full company profile